SCHEMBL120583

SCHEMBL120583

CCSSNC(=N)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28209790 0.74 MAPK1 (0.33)
Guanidine SCHEMBL27984897 0.72 NOS1 (0.53)
SCHEMBL3075811 0.71 KDM4E (0.33)
SCHEMBL7125618 0.70 TSHR (0.53)
SCHEMBL6908839 0.67
SCHEMBL28974853 0.65
SCHEMBL13515121 0.64
SCHEMBL4285470 0.64
SCHEMBL2011013 0.62
SCHEMBL11262636 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023076811-A1 COMBINATION THERAPIES WITH CHIMERIC ANTIGEN RECEPTORS Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) 2023-05-04 WO claimed
US-20210060123-A1 THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN LEVICEPT LTD (GB) 2021-03-04 US claimed
US-20190317040-A1 DEVICES AND METHODS FOR TARGET MOLECULE CHARACTERIZATION ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2019-10-17 US claimed
US-20190292246-A1 COMBINATION THERAPY OF A CELL BASED THERAPY AND A MICROGLIA IMHIBITOR JUNO THERAPEUTICS, INC. (US) 2019-09-26 US claimed
EP-3534940-A1 COMBINATION THERAPY OF A CELL BASED THERAPY AND A MICROGLIA INHIBITOR Juno Therapeutics, Inc. (US) 2019-09-11 EP claimed
EP-2111135-B1 ORAL CARE IMPLEMENT HAVING FLUID DELIVERY SYSTEM COLGATE PALMOLIVE CO (US) 2018-07-04 EP claimed
US-20180161392-A1 THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN LEVICEPT LTD (GB) 2018-06-14 US claimed
WO-2018093591-A1 COMBINATION THERAPY OF A CELL BASED THERAPY AND A MICROGLIA INHIBITOR JUNO THERAPEUTICS, INC. (US) 2018-05-24 WO claimed
EP-2117376-B1 ORAL CARE IMPLEMENT HOUSING AN ORAL CARE AGENT COLGATE PALMOLIVE CO (US) 2017-11-15 EP claimed
EP-2825208-B1 P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE LEVICEPT LTD (GB) 2017-05-17 EP claimed
EP-1855686-A1 USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN Pfizer Limited (GB) 2007-11-21 EP claimed
WO-2007123777-A2 INHIBITION OF HIF-1 ACTIVATION FOR ANTI-TUMOR AND ANTI-INFLAMMATORY RESPONSES DUKE UNIVERSITY (US) 2007-11-01 WO claimed
WO-2006092691-A1 USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN PFIZER LIMITED (GB) 2006-09-08 WO claimed
EP-0814792-B1 MERCAPTO AND SELENO DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE CHILDRENS HOSP MEDICAL CENTER (US) 2003-05-28 EP claimed
US-5985917-A ANTITUMOR AGENTS AND ENZYME INHIBITORS CHILDREN'S HOSPITAL MEDICAL CENTER (US) 1999-11-16 US claimed
US-5929063-A SELECTIVELY INHIBITS THE INDUCIBLE ISOFORM TO PREVENT OVER-INHIBITION; FOR DISORDERS WHERE THE ENZYME PLAYS A ROLE, E.G SYSTEMIC HYPOTENSION, SEPTIC SHOCK AND CYTOKINE THERAPY CHILDREN'S HOSPITAL MEDICAL CENTER (US) 1999-07-27 US claimed
EP-0814792-A1 MERCAPTO AND SELENO DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE CHILDREN'S HOSPITAL MEDICAL CENTER (US) 1998-01-07 EP claimed
WO-1997045108-A1 GUANIDINO DERIVATIVES AS INHIBITORS OF THE CYTOTOXIC EFFECT OF PEROXYNITRITE CHILDREN'S HOSPITAL MEDICAL CENTER (US) 1997-12-04 WO claimed
WO-1997032575-A1 MERCAPTO DERIVATIVES AS INHIBITORS OF CYCLOOXYGENASES CHILDREN'S HOSPITAL MEDICAL CENTER (US) 1997-09-12 WO claimed
WO-1996030007-A1 MERCAPTO AND SELENO DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHASE CHILDREN'S HOSPITAL MEDICAL CENTER (US) 1996-10-03 WO claimed